323 related articles for article (PubMed ID: 18789365)
1. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development.
Smeesters PR; Mardulyn P; Vergison A; Leplae R; Van Melderen L
Vaccine; 2008 Oct; 26(46):5835-42. PubMed ID: 18789365
[TBL] [Abstract][Full Text] [Related]
2. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS.
Smeesters PR; Dramaix M; Van Melderen L
Vaccine; 2010 Jan; 28(4):883-5. PubMed ID: 19963033
[No Abstract] [Full Text] [Related]
3. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
5. Emerging fluoroquinolone-non-susceptible group A streptococci in two different paediatric populations.
Smeesters PR; Vergison A; Junior DC; Van Melderen L
Int J Antimicrob Agents; 2009 Jul; 34(1):44-9. PubMed ID: 19269141
[TBL] [Abstract][Full Text] [Related]
6. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape.
Smeesters PR; Vergison A; Campos D; de Aguiar E; Miendje Deyi VY; Van Melderen L
PLoS One; 2006 Dec; 1(1):e10. PubMed ID: 17183632
[TBL] [Abstract][Full Text] [Related]
7. M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns.
Tewodros W; Kronvall G
J Clin Microbiol; 2005 Sep; 43(9):4369-76. PubMed ID: 16145079
[TBL] [Abstract][Full Text] [Related]
8. Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates.
Shulman ST; Tanz RR; Dale JB; Beall B; Kabat W; Kabat K; Cederlund E; Patel D; Rippe J; Li Z; Sakota V;
Clin Infect Dis; 2009 Jul; 49(1):78-84. PubMed ID: 19480575
[TBL] [Abstract][Full Text] [Related]
9. Group A streptococcal infections: trend and strain emm typing in an area of central Italy, 1985-2002.
Mencarelli M; Corbisiero R; Padula MG; Galgani I; Stolzuoli L; Cellesi C
Epidemiol Infect; 2005 Dec; 133(6):1107-11. PubMed ID: 16274508
[TBL] [Abstract][Full Text] [Related]
10. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
11. Molecular heterogeneity among north Indian isolates of Group A Streptococcus.
Sagar V; Bakshi DK; Nandi S; Ganguly NK; Kumar R; Chakraborti A
Lett Appl Microbiol; 2004; 39(1):84-8. PubMed ID: 15189292
[TBL] [Abstract][Full Text] [Related]
12. Group A streptococcus epidemiology and vaccine implications.
Cohen-Poradosu R; Kasper DL
Clin Infect Dis; 2007 Oct; 45(7):863-5. PubMed ID: 17806050
[No Abstract] [Full Text] [Related]
13. Streptococcus pyogenes emm and T types within a decade, 1996-2005: implications for epidemiology and future vaccines.
Nir-Paz R; Korenman Z; Ron M; Michael-Gayego A; Cohen-Poradosu R; Valinsky L; Beall B; Moses AE
Epidemiol Infect; 2010 Jan; 138(1):53-60. PubMed ID: 19480723
[TBL] [Abstract][Full Text] [Related]
14. Genetically diverse group A streptococci from children in far-western Nepal share high genetic relatedness with isolates from other countries.
Sakota V; Fry AM; Lietman TM; Facklam RR; Li Z; Beall B
J Clin Microbiol; 2006 Jun; 44(6):2160-6. PubMed ID: 16757615
[TBL] [Abstract][Full Text] [Related]
15. Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002.
Shulman ST; Tanz RR; Kabat W; Kabat K; Cederlund E; Patel D; Li Z; Sakota V; Dale JB; Beall B;
Clin Infect Dis; 2004 Aug; 39(3):325-32. PubMed ID: 15306998
[TBL] [Abstract][Full Text] [Related]
16. [Distribution of emm genotypes and antibiotic susceptibility of Streptococcus pyogenes strains: analogy with the vaccine in development].
Arslan U; Oryaşın E; Eskin Z; Türk Dağı H; Fındık D; Tuncer I; Bozdoğan B
Mikrobiyol Bul; 2013 Apr; 47(2):318-23. PubMed ID: 23621731
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
18. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
20. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
